Evidence map›Paper›PMID 18940803›Full record

ArticleThe Journal of biological chemistry2008

Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets.

Lin Yang, Li Zhang, Qiuyu Wu, Douglas D Boyd

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Effect of Lacking ZKSCAN3 on Autophagy, Lysosomal Biogenesis and Senescence.International journal of molecular sciences · 2023
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. ZKSCAN3 in severe bacterial lung infection and sepsis-induced immunosuppression.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lin YangDepartment of Cancer Biology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA.
Li Zhang
Qiuyu Wu
Douglas D Boyd
The University of Texas MD Anderson Cancer Center · US

Funding

UROKINASE RECEPTOR EXPRESSION--COLON CANCERR01CA058311 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOYD, DOUGLAS D. · 1994 to 2010
$2.2M
Regulation of type IV collagenase expressionR01DE010845 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOYD, DOUGLAS D. · 1994 to 2007
$1.7M
Regulation of urokinase receptor expression in colon cancerR56CA058311 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOYD, DOUGLAS D. · 2008 to 2008
$288k
NCI NIH HHS CA58311NCI NIH HHS R01 CA058311NCI NIH HHS R56 CA058311NIDCR NIH HHS DE10845NIDCR NIH HHS R01 DE010845
6 · The paper itself

Abstract

We previously described the novel zinc finger protein ZKSCAN3 as a new "driver" of colon cancer progression. To investigate the underlying mechanism and because the predicted structural features (tandem zinc fingers) are often present in transcription factors, we hypothesized that ZKSCAN3 regulates the expression of a gene(s) favoring tumor progression. We employed unbiased screening to identify a DNA binding motif and candidate downstream genes. Cyclic amplification and selection of targets using a random oligonucleotide library and ZKSCAN3 protein identified KRDGGG as the DNA recognition motif. In expression profiling, 204 genes were induced 2-29-fold, and 76 genes reduced 2-5-fold by ZKSCAN3. To enrich for direct targets, we eliminated genes under-represented (<3) for the ZKSCAN3 binding motif (identified by CAST-ing) in 2 kilobases of regulatory sequence. Up-regulated putative downstream targets included genes contributing to growth (c-Met-related tyrosine kinase (MST1R), MEK2; the guanine nucleotide exchanger RasGRP2, insulin-like growth factor-2, integrin beta 4), cell migration (MST1R), angiogenesis (vascular endothelial growth factor), and proteolysis (MMP26; cathepsin D; PRSS3 (protease serine 3)). We pursued integrin beta 4 (induced up to 6-fold) as a candidate target because it promotes breast cancer tumorigenicity and stimulates phosphatidyl 3-kinase implicated in colorectal cancer progression. ZKSCAN3 overexpression/silencing modulated integrin beta 4 expression, confirming the array analysis. Moreover, ZKSCAN3 bound to the integrin beta 4 promoter in vitro and in vivo, and the integrin beta 4-derived ZKSCAN3 motif fused upstream of a tk-Luc reporter conferred ZKSCAN3 sensitivity. Integrin beta 4 knockdown by short hairpin RNA countered ZKSCAN3-augmented anchorage-independent colony formation. We also demonstrate vascular endothelial growth factor as a direct ZKSCAN3 target. Thus, ZKSCAN3 regulates the expression of several genes favoring tumor progression including integrin beta 4.

Indexed as

Gene Expression RegulationAnimalsCell Line, TumorColonic NeoplasmsGene Expression Regulation, NeoplasticHumansIntegrin beta4MaleMiceMice, NudeModels, BiologicalNeoplasm TransplantationTranscription FactorsVascular Endothelial Growth Factor AZinc FingersIntegrin beta4Transcription FactorsVascular Endothelial Growth Factor AZKSCAN3 protein, humanZKSCAN3 protein, mouse

Identifiers

PMID18940803
PMCPMC2596387
OpenAlexW2004630001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.